Feline MYBPC Gene Mutation Detection for Hypertrophic Cardiomyopathy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack reliable diagnostic tools for detecting hypertrophic cardiomyopathy in domestic cats, particularly Maine Coon cats, which is a common and severe disease causing heart failure and sudden death.
Innovation Solution
The development of genetic testing methods focusing on mutations in the cardiac myosin binding protein-C (MYBPC) gene, specifically identifying a cytosine mutation at position 66 (codon 31) of exon 3, to diagnose and predict the likelihood of hypertrophic cardiomyopathy in cats.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If genetic testing methods are developed to detect MYBPC mutations, then diagnostic reliability is improved, but device complexity increases
Solution Approach 1:
The patent extracts and focuses on a specific diagnostic target (MYBPC gene mutations) rather than attempting comprehensive cardiac disease testing. By isolating the specific genetic marker at position 66 of exon 3, the method achieves high diagnostic reliability for hypertrophic cardiomyopathy while keeping the testing protocol manageable and focused.
Solution Approach 2:
The patent changes the diagnostic parameter from general cardiac function assessment to specific genetic sequence analysis. By detecting nucleotide changes (e.g., G to C transition) at a predetermined position in the MYBPC gene, the method provides reliable diagnostic information through molecular genetics rather than complex phenotypic evaluation.
2Loss of time
If asymptomatic cats are screened using genetic testing, then early intervention capability is improved, but measurement precision requirements increase
Solution Approach 1:
The patent enables preliminary detection of hypertrophic cardiomyopathy through genetic testing of asymptomatic cats before clinical symptoms manifest. By analyzing the MYBPC gene sequence in advance, the method allows early intervention and management strategies to be implemented, preventing disease progression and improving prognosis.
Solution Approach 2:
The patent uses molecular copying techniques (PCR amplification, DNA sequencing) to create and analyze copies of the MYBPC gene sequence. This allows precise detection of mutations without requiring direct observation of cardiac pathology, enabling early screening through genetic replication and analysis of the DNA template.
3Object-generated harmful factors
If breeding population management is implemented based on genetic testing, then disease propagation reduction is improved, but loss of information about carrier status increases
Solution Approach 1:
The patent converts the potentially harmful effect of genetic testing into a beneficial breeding management tool. By identifying cats with MYBPC mutations, the method enables selective removal from the breeding population, thereby reducing disease propagation. The testing process itself becomes the mechanism for disease control rather than merely informational.
Solution Approach 2:
The patent applies local quality control by focusing genetic testing on specific high-risk individuals (cats with family history of hypertrophic cardiomyopathy) rather than comprehensive population screening. This targeted approach reduces the information loss problem by concentrating testing resources on animals where the MYBPC mutation is most likely to be present, maintaining better carrier status awareness in the breeding population.
Data Source
AI summary
The invention pertains to methods for detecting the presence or absence of a mutation associated with hypertrophic cardiomyopathy in cats, particularly domesticated cats, and more particularly Maine Coon cats. The methods include detecting the presence or absence of a mutation in the feline MYBPC gene, and identifying feline subjects that have or are at risk of developing hypertrophic cardiomyopathy.